Get the Stockscreener App
0.2441
3.90%
-0.0099
After Hours:
.24
-0.0041
-1.68%
Allakos Inc stock is traded at $0.2441, with a volume of 4.10M.
It is down -3.90% in the last 24 hours and down -79.49% over the past month.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.
See More
Previous Close:
$0.254
Open:
$0.2468
24h Volume:
4.10M
Relative Volume:
2.44
Market Cap:
$21.81M
Revenue:
-
Net Income/Loss:
$-166.14M
P/E Ratio:
-0.1271
EPS:
-1.92
Net Cash Flow:
$-139.92M
1W Performance:
-76.30%
1M Performance:
-79.49%
6M Performance:
-73.56%
1Y Performance:
-81.92%
1-Day Range:
$0.235
$0.2532
1-Week Range:
$0.23
$1.26
52-Week Range:
$0.23
$1.69
Allakos Inc Stock (ALLK) Company Profile
Name
Allakos Inc
Sector
Industry
Phone
650-597-5002
Address
825 INDUSTRIAL ROAD, SAN CARLOS, CA
Compare ALLK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLK
Allakos Inc
|
0.2441 | 21.81M | 0 | -166.14M | -139.92M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Allakos Inc Stock (ALLK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-17-24 | Downgrade | Jefferies | Buy → Hold |
| Jan-16-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-18-23 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-08-23 | Resumed | Jefferies | Buy |
| Sep-27-23 | Initiated | JMP Securities | Mkt Outperform |
| May-12-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-07-23 | Initiated | Piper Sandler | Overweight |
| Sep-12-22 | Downgrade | SMBC Nikko | Neutral → Underperform |
| Dec-22-21 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-22-21 | Downgrade | Cowen | Outperform → Market Perform |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Dec-22-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-22-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-26-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-15-21 | Initiated | Cowen | Outperform |
| May-18-21 | Initiated | H.C. Wainwright | Buy |
| Feb-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-15-21 | Initiated | BofA Securities | Buy |
| Dec-21-20 | Initiated | SVB Leerink | Outperform |
| Feb-27-20 | Initiated | Barclays | Underweight |
| Feb-04-20 | Resumed | Goldman | Neutral |
| Aug-13-18 | Initiated | Goldman | Neutral |
| Aug-13-18 | Initiated | Jefferies | Buy |
| Aug-13-18 | Initiated | William Blair | Outperform |
View All
Allakos Inc Stock (ALLK) Latest News
Allakos plunges 75% on phase 1 data for urticaria asset - MSN
Allakos stock tumbles following AK006 trial discontinuation - MSN
Allakos (NASDAQ:ALLK) Cut to Hold at Piper Sandler - Defense World
Allakos (NASDAQ:ALLK) Cut to Hold at Citizens Jmp - Defense World
Allakos Stock Craters To Record Low On Lead Drug Setback: Retail Hopes Fade - MSN
Allakos stock tanks after company announces mass layoffs - MSN
Allakos to cease AK006 development after trial setback - MSN
Allakos cuts 75% of workforce after chronic hives trial failure - Clinical Trials Arena
Allakos decimated as Phase I Trial of AK006 fails - The Pharma Letter
Allakos shares fall as Jefferies cuts price target to $0.40 - MSN
Allakos stock hits 52-week low at $0.3 amid market challenges - Investing.com Nigeria
Best, worst of biotech times: One company soars, another stumbles and a third seeks funds - The Business Journals
Bay Area biotech firm suddenly on brink of collapse after trial flops - SFGATE
S&P 500 Falls Over 100 Points; Dada Nexus Shares Spike Higher - Benzinga
Stock market news: Planet Image International surged by 160.47% while Allakos is still declining by 80.30% during mid day trading - Business Upturn
Allakos Inc. (ALLK) PT Lowered to $0.40 at Jefferies - StreetInsider.com
Dow Edges Higher; AT&T Posts Upbeat Earnings - Benzinga
Allakos Shares Plummet to All-Time Low After Lead Candidate Failure - MarketWatch
Stock market today: Allakos dropped by 76.37% whereas Onconetix jumped by 77.10% in early trading - Business Upturn
Nasdaq Dips 3%; Chicago Fed National Activity Index Rises In December - Benzinga
Allakos stock tumbles following AK006 trial discontinuation By Investing.com - Investing.com Australia
Allakos Drops AK006, Cuts 75% of Staff After Study Failure - MarketWatch
Allakos Restructures Amid AK006 Program Discontinuation - TipRanks
Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring - The Manila Times
Allakos (ALLK) will discontinue further development of AK006 - StreetInsider.com
Allakos Halts AK006 Development After Failed CSU Trial, Cuts 75% of Workforce - StockTitan
Discover US Penny Stocks To Watch In January 2025 - Simply Wall St
Allakos Inc. (NASDAQ:ALLK) Shares Sold by Barclays PLC - Defense World
Jane Street Group LLC Has $34,000 Stake in Allakos Inc. (NASDAQ:ALLK) - Defense World
Atopic Dermatitis Clinical and Non-Clinical Studies, Key - openPR
BIOTECH MARKET RESEARCH $ALLK | Ep. 550 - substack.com
Geode Capital Management LLC Purchases 80,763 Shares of Allakos Inc. (NASDAQ:ALLK) - Defense World
Institutional owners may take dramatic actions as Allakos Inc.'s (NASDAQ:ALLK) recent 11% drop adds to one-year losses - Simply Wall St
Eosinophilic Gastroenteritis Treatment Market 2032: EMA, - openPR
Barclays PLC Lowers Stock Position in Allakos Inc. (NASDAQ:ALLK) - Defense World
Allakos Inc. (NASDAQ:ALLK) Short Interest Down 15.7% in December - Defense World
Allakos Inc. (NASDAQ:ALLK) Short Interest Update - MarketBeat
Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm - Kilgore News Herald
BNP Paribas Financial Markets Sells 103,658 Shares of Allakos Inc. (NASDAQ:ALLK) - Defense World
Contrasting GT Biopharma (NASDAQ:GTBP) and Allakos (NASDAQ:ALLK) - Defense World
Allakos Inc Stock (ALLK) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):